Skip to main navigation Skip to search Skip to main content

LYL314-101, A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of Rondecabtagene Autoleucel, A CD19/CD20 Dual Targeting Chimeric Antigen Receptor T-Cell Therapy in Participants with Aggressive B-Cell Non-Hodgkin Lymphoma

  • Fiorenza, Sam (Primary Chief Investigator (PCI))
  • Chin, Collin (Chief Investigator (CI))
  • Chin, Collin (Chief Investigator (CI))
  • Cheah, Chan Yoon (Chief Investigator (CI))

Project: Research

Project Details

StatusActive
Effective start/end date6/03/26 → 5/03/28

Keywords

  • clinical trials
  • LYL314
  • T-CELL THERAPY
  • B-CELL NON-HODGKIN LYMPHOMA

Clinical Trial Phase

  • Phase I
  • Phase II
  • External Sponsor